{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:02:34Z","timestamp":1789434154708,"version":"build-2803163510"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natural Science Foundation of Shanghai","award":["22ZR1438800"],"award-info":[{"award-number":["22ZR1438800"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The high clinical recurrence rate of colorectal cancer (CRC) is driven by the survival of residual tumor cells that evade therapy-induced death by entering a dormant state. While dormancy is a recognized mechanism of treatment resistance, the molecular drivers governing this \"quiescent reservoir\" and its associated vulnerabilities remain poorly characterized, limiting the development of strategies to eradicate these dormant seeds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a COAD-specific Dormancy Score (CADS) derived from NMF analysis of\u2009~\u200969,000 single cells to quantify and identify a dormant subpopulation at single-cell resolution. Mechanistically, the IFN-\u03b2\/cDC1 axis and its downstream MEK\/ERK dependency were validated using a GFP-p27K- dormancy reporter system, spatial transcriptomics, and CRISPR\/Cas9-mediated Ifnar1 knockdown. Finally, the synergistic efficacy of anti-PD-1 combined with MEK inhibition (Trametinib) was evaluated in orthotopic CRC mouse models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The CADS effectively identified a distinct dormant subpopulation in CRC characterized by profound G0\/G1 arrest, enhanced stemness, and multi-drug resistance. We uncovered a novel evasion mechanism mediated by the hijacking of IFN-\u03b2 signaling. Conventionally recognized for its anti-proliferative roles, IFN-\u03b2 signaling is exploited by surviving tumor cells to enter a deep quiescent state. This phenotype acts as a biological reservoir that fuels intratumoral heterogeneity and underpins the relapse of colorectal tumors by conferring resistance to conventional cytotoxic regimens. Effective anti-PD-1 therapy paradoxically enriches this dormant population via an enhanced IFN-\u03b2-conventional type 1 dendritic cell (cDC1) axis. Mechanistically, IFN-\u03b2\u2013induced dormancy depends on MEK\/ERK pathway activity, which sustains survival while suppressing apoptosis. This creates a synthetic lethal vulnerability: MEK inhibition (e.g., Trametinib) synergizes with IFN-\u03b2 to re-sensitize dormant cells to apoptosis. Consequently, combining Trametinib with anti-PD-1 therapy overcomes this evasion mechanism, eliminates the dormant subpopulation, remodels the immune microenvironment, and shows strong synergistic efficacy in preclinical models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our work redefines an immune\u2013cell death paradox, revealing how tumors exploit IFN-\u03b2 to evade therapy. We propose CADS as a translational biomarker for identifying tumors reliant on this pathway and validate a mechanism-based combination therapy that selectively targets dormancy-associated death resistance, offering a promising strategy to improve CRC outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03768-6","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:19:04Z","timestamp":1782573544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["From paradox to target: IFN-\u03b2 hijacks MEK signaling to drive a cell death-evading dormant phenotype in colorectal cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Yangyang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haigang","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanggang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanglei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanxuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengfan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangchou","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunchao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"1","key":"3768_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"issue":"5","key":"3768_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","volume":"31","author":"JJ Loh","year":"2024","unstructured":"Loh JJ, Ma S. Hallmarks of cancer stemness. Cell Stem Cell. 2024;31(5):617\u201339.","journal-title":"Cell Stem Cell"},{"issue":"7","key":"3768_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1158\/2159-8290.CD-19-0015","volume":"9","author":"S Yuan","year":"2019","unstructured":"Yuan S, Norgard RJ, Stanger BZ. Cellular plasticity in cancer. Cancer Discov. 2019;9(7):837\u201351.","journal-title":"Cancer Discov"},{"issue":"3","key":"3768_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4103\/aja.aja_41_18","volume":"21","author":"AM Blee","year":"2019","unstructured":"Blee AM, Huang H. Lineage plasticity-mediated therapy resistance in prostate cancer. Asian J Androl. 2019;21(3):241\u20138.","journal-title":"Asian J Androl"},{"issue":"8","key":"3768_CR5","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s43018-023-00595-y","volume":"4","author":"A Perez-Gonzalez","year":"2023","unstructured":"Perez-Gonzalez A, Bevant K, Blanpain C. Cancer cell plasticity during tumor progression, metastasis and response to therapy. Nat Cancer. 2023;4(8):1063\u201382.","journal-title":"Nat Cancer"},{"issue":"8","key":"3768_CR6","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1158\/2159-8290.CD-23-0225","volume":"13","author":"A Davies","year":"2023","unstructured":"Davies A, Zoubeidi A, Beltran H, Selth LA. The transcriptional and epigenetic landscape of cancer cell lineage plasticity. Cancer Discov. 2023;13(8):1771\u201388.","journal-title":"Cancer Discov"},{"issue":"9","key":"3768_CR7","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s43018-022-00402-0","volume":"3","author":"A Alvarez-Varela","year":"2022","unstructured":"Alvarez-Varela A, Novellasdemunt L, Barriga FM, Hernando-Momblona X, Canellas-Socias A, Cano-Crespo S, et al. Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy. Nat Cancer. 2022;3(9):1052\u201370.","journal-title":"Nat Cancer"},{"issue":"3","key":"3768_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.trecan.2023.11.003","volume":"10","author":"CJ Tape","year":"2024","unstructured":"Tape CJ. Plastic persisters: revival stem cells in colorectal cancer. Trends Cancer. 2024;10(3):185\u201395.","journal-title":"Trends Cancer"},{"issue":"3","key":"3768_CR9","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"7924","key":"3768_CR10","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41586-022-05043-y","volume":"608","author":"Y Ohta","year":"2022","unstructured":"Ohta Y, Fujii M, Takahashi S, Takano A, Nanki K, Matano M, et al. Cell-matrix interface regulates dormancy in human colon cancer stem cells. Nature. 2022;608(7924):784\u201394.","journal-title":"Nature"},{"issue":"1","key":"3768_CR11","first-page":"7","volume":"12","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang CH, Li N. Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence. Mil Med Res. 2025;12(1):7.","journal-title":"Mil Med Res"},{"issue":"7","key":"3768_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41568-020-0263-0","volume":"20","author":"TG Phan","year":"2020","unstructured":"Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20(7):398\u2013411.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3768_CR13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","volume":"184","author":"SK Rehman","year":"2021","unstructured":"Rehman SK, Haynes J, Collignon E, Brown KR, Wang Y, Nixon AML, et al. Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy. Cell. 2021;184(1):226-242 e221.","journal-title":"Cell"},{"issue":"3","key":"3768_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrclinonc.2016.144","volume":"14","author":"M Mohme","year":"2017","unstructured":"Mohme M, Riethdorf S, Pantel K. Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol. 2017;14(3):155\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"3768_CR15","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167(6):1540-1554 e1512.","journal-title":"Cell"},{"issue":"6745","key":"3768_CR16","doi-asserted-by":"publisher","first-page":"eadr3026","DOI":"10.1126\/science.adr3026","volume":"388","author":"DK Chiu","year":"2025","unstructured":"Chiu DK, Zhang X, Cheng BY, Liu Q, Hayashi K, Yu B, et al. Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity. Science. 2025;388(6745):eadr3026.","journal-title":"Science"},{"issue":"24","key":"3768_CR17","doi-asserted-by":"publisher","first-page":"6754","DOI":"10.1016\/j.cell.2025.09.029","volume":"188","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Guo Y, Liu Z, Sun Y, Yang X, Chen M, et al. Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance. Cell. 2025;188(24):6754-6773 e6729.","journal-title":"Cell"},{"issue":"22","key":"3768_CR18","doi-asserted-by":"publisher","first-page":"6335","DOI":"10.1016\/j.cell.2025.08.013","volume":"188","author":"Y Han","year":"2025","unstructured":"Han Y, Sarkar H, Xu Z, Lopez-Darwin S, Wei Y, Hang X, et al. Tumors hijack macrophages for iron supply to promote bone metastasis and anemia. Cell. 2025;188(22):6335-6354 e6326.","journal-title":"Cell"},{"issue":"5","key":"3768_CR19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41(5):830\u201342.","journal-title":"Immunity"},{"issue":"2","key":"3768_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","volume":"55","author":"E Duong","year":"2022","unstructured":"Duong E, Fessenden TB, Lutz E, Dinter T, Yim L, Blatt S, et al. Type I interferon activates MHC class I-dressed CD11b(+) conventional dendritic cells to promote protective anti-tumor CD8(+) T cell immunity. Immunity. 2022;55(2):308-323 e309.","journal-title":"Immunity"},{"issue":"8","key":"3768_CR21","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71.","journal-title":"Nucleic Acids Res"},{"issue":"7757","key":"3768_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd, et al. Next-generation characterization of the cancer cell line encyclopedia. Nature. 2019;569(7757):503\u20138.","journal-title":"Nature"},{"issue":"Database issue","key":"3768_CR23","first-page":"D955","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(Database issue):D955-961.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"3768_CR24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccr.2007.11.014","volume":"12","author":"AA Ahmed","year":"2007","unstructured":"Ahmed AA, Mills AD, Ibrahim AE, Temple J, Blenkiron C, Vias M, et al. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell. 2007;12(6):514\u201327.","journal-title":"Cancer Cell"},{"issue":"4","key":"3768_CR25","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1158\/1078-0432.CCR-06-1304","volume":"13","author":"LN Harris","year":"2007","unstructured":"Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007;13(4):1198\u2013207.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3768_CR26","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/sj.bjc.6604322","volume":"98","author":"PK Julka","year":"2008","unstructured":"Julka PK, Chacko RT, Nag S, Parshad R, Nair A, Oh DS, et al. A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. Br J Cancer. 2008;98(8):1327\u201335.","journal-title":"Br J Cancer"},{"issue":"2","key":"3768_CR27","doi-asserted-by":"publisher","first-page":"101399","DOI":"10.1016\/j.xcrm.2024.101399","volume":"5","author":"X Bao","year":"2024","unstructured":"Bao X, Li Q, Chen D, Dai X, Liu C, Tian W, et al. A multiomics analysis-assisted deep learning model identifies a macrophage-oriented module as a potential therapeutic target in colorectal cancer. Cell Rep Med. 2024;5(2):101399.","journal-title":"Cell Rep Med"},{"issue":"2","key":"3768_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/path.2547","volume":"218","author":"C Denkert","year":"2009","unstructured":"Denkert C, Budczies J, Darb-Esfahani S, Gyorffy B, Sehouli J, Konsgen D, et al. A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol. 2009;218(2):273\u201380.","journal-title":"J Pathol"},{"issue":"5","key":"3768_CR29","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1182\/blood-2006-12-059790","volume":"110","author":"SS Winter","year":"2007","unstructured":"Winter SS, Jiang Z, Khawaja HM, Griffin T, Devidas M, Asselin BL, et al. Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. Blood. 2007;110(5):1429\u201338.","journal-title":"Blood"},{"issue":"4","key":"3768_CR30","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1535-7163.MCT-09-0764","volume":"9","author":"CK Augustine","year":"2010","unstructured":"Augustine CK, Jung SH, Sohn I, Yoo JS, Yoshimoto Y, Olson JA Jr., et al. Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. Mol Cancer Ther. 2010;9(4):779\u201390.","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"3768_CR31","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","volume":"184","author":"K Pelka","year":"2021","unstructured":"Pelka K, Hofree M, Chen JH, Sarkizova S, Pirl JD, Jorgji V, et al. Spatially organized multicellular immune hubs in human colorectal cancer. Cell. 2021;184(18):4734-4752 e4720.","journal-title":"Cell"},{"issue":"10","key":"3768_CR32","doi-asserted-by":"publisher","first-page":"e14123","DOI":"10.15252\/emmm.202114123","volume":"13","author":"F Uhlitz","year":"2021","unstructured":"Uhlitz F, Bischoff P, Peidli S, Sieber A, Trinks A, Luthen M, et al. Mitogen-activated protein kinase activity drives cell trajectories in colorectal cancer. EMBO Mol Med. 2021;13(10):e14123.","journal-title":"EMBO Mol Med"},{"issue":"6257","key":"3768_CR33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207\u201311.","journal-title":"Science"},{"issue":"1","key":"3768_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/2326-6066.CIR-16-0019","volume":"5","author":"T Nathanson","year":"2017","unstructured":"Nathanson T, Ahuja A, Rubinsteyn A, Aksoy BA, Hellmann MD, Miao D, et al. Somatic mutations and neoepitope homology in melanomas treated with CTLA-4 blockade. Cancer Immunol Res. 2017;5(1):84\u201391.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"3768_CR35","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171(4):934-949 e916.","journal-title":"Cell"},{"issue":"10","key":"3768_CR36","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","volume":"24","author":"N Auslander","year":"2018","unstructured":"Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018;24(10):1545\u20139.","journal-title":"Nat Med"},{"issue":"9","key":"3768_CR37","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s12276-020-00493-8","volume":"52","author":"JW Cho","year":"2020","unstructured":"Cho JW, Hong MH, Ha SJ, Kim YJ, Cho BC, Lee I, et al. Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer. Exp Mol Med. 2020;52(9):1550\u201363.","journal-title":"Exp Mol Med"},{"issue":"3","key":"3768_CR38","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25(3):462\u20139.","journal-title":"Nat Med"},{"issue":"13","key":"3768_CR39","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573-3587 e3529.","journal-title":"Cell"},{"issue":"12","key":"3768_CR40","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods. 2019;16(12):1289\u201396.","journal-title":"Nat Methods"},{"issue":"1","key":"3768_CR41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13058-022-01503-5","volume":"24","author":"Q Ren","year":"2022","unstructured":"Ren Q, Khoo WH, Corr AP, Phan TG, Croucher PI, Stewart SA. Gene expression predicts dormant metastatic breast cancer cell phenotype. Breast Cancer Res. 2022;24(1):10.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"3768_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood.2018880930","volume":"134","author":"WH Khoo","year":"2019","unstructured":"Khoo WH, Ledergor G, Weiner A, Roden DL, Terry RL, McDonald MM, et al. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood. 2019;134(1):30\u201343.","journal-title":"Blood"},{"issue":"7269","key":"3768_CR43","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108\u201312.","journal-title":"Nature"},{"issue":"1","key":"3768_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13073-020-0721-z","volume":"12","author":"J Fu","year":"2020","unstructured":"Fu J, Li K, Zhang W, Wan C, Zhang J, Jiang P, et al. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 2020;12(1):21.","journal-title":"Genome Med"},{"issue":"10","key":"3768_CR45","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138.","journal-title":"Nat Med"},{"issue":"3","key":"3768_CR46","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a cancer dependency map. Cell. 2017;170(3):564-576 e516.","journal-title":"Cell"},{"issue":"4","key":"3768_CR47","doi-asserted-by":"publisher","first-page":"379","DOI":"10.26502\/jbsb.5107072","volume":"6","author":"T Liefeld","year":"2023","unstructured":"Liefeld T, Huang E, Wenzel AT, Yoshimoto K, Sharma AK, Sicklick JK, et al. NMF Clustering: Accessible NMF-based Clustering Utilizing GPU Acceleration. J Bioinform Syst Biol. 2023;6(4):379\u201383.","journal-title":"J Bioinform Syst Biol"},{"key":"3768_CR48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-1-0716-3882-8_11","volume":"2811","author":"F Landum","year":"2024","unstructured":"Landum F, Correia AL. A live tracker of dormant disseminated tumor cells. Methods Mol Biol. 2024;2811:155\u201364.","journal-title":"Methods Mol Biol"},{"issue":"5","key":"3768_CR49","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.devcel.2026.02.020","volume":"61","author":"H Geng","year":"2026","unstructured":"Geng H, Wang H, Zhang C, Zhou Y, Zhong Y, Zhu Z, et al. Unleashing T cell surveillance for the eradication of quiescent persister tumor cells resistant to neoadjuvant chemotherapy. Dev Cell. 2026;61(5):995-1011 e1012.","journal-title":"Dev Cell"},{"issue":"1","key":"3768_CR50","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12885-025-13834-5","volume":"25","author":"C Chen","year":"2025","unstructured":"Chen C, Fu Q, Wang L, Tanaka S, Imajo M. Establishment of a novel mouse model of colorectal cancer by orthotopic transplantation. BMC Cancer. 2025;25(1):405.","journal-title":"BMC Cancer"},{"key":"3768_CR51","doi-asserted-by":"publisher","first-page":"104397","DOI":"10.1016\/j.ebiom.2022.104397","volume":"87","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Wang S, Wu W, Ling J, Li H, Jia Q, et al. Sustained activation of EGFR-ERK1\/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer. EBioMedicine. 2023;87:104397.","journal-title":"EBioMedicine"},{"issue":"6","key":"3768_CR52","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/laban.254","volume":"42","author":"A Faustino-Rocha","year":"2013","unstructured":"Faustino-Rocha A, Oliveira PA, Pinho-Oliveira J, Teixeira-Guedes C, Soares-Maia R, da Costa RG, et al. Estimation of rat mammary tumor volume using caliper and ultrasonography measurements. Lab Anim (NY). 2013;42(6):217\u201324.","journal-title":"Lab Anim (NY)"},{"issue":"7","key":"3768_CR53","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410.","journal-title":"PLoS Biol"},{"key":"3768_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"issue":"20","key":"3768_CR55","doi-asserted-by":"publisher","first-page":"9363","DOI":"10.1073\/pnas.92.20.9363","volume":"92","author":"GP Dimri","year":"1995","unstructured":"Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995;92(20):9363\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3768_CR56","doi-asserted-by":"publisher","first-page":"59","DOI":"10.7150\/jca.123742","volume":"17","author":"J Hu","year":"2026","unstructured":"Hu J, Zhou W, Zhao Y, Li P, Zhao Z, Wang W, et al. Cancer cell dormancy and chemotherapy resistance. J Cancer. 2026;17(1):59\u201373.","journal-title":"J Cancer"},{"issue":"7936","key":"3768_CR57","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41586-022-05402-9","volume":"611","author":"A Canellas-Socias","year":"2022","unstructured":"Canellas-Socias A, Cortina C, Hernando-Momblona X, Palomo-Ponce S, Mulholland EJ, Turon G, et al. Metastatic recurrence in colorectal cancer arises from residual EMP1(+) cells. Nature. 2022;611(7936):603\u201313.","journal-title":"Nature"},{"issue":"1","key":"3768_CR58","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13059-021-02581-y","volume":"23","author":"SC Zheng","year":"2022","unstructured":"Zheng SC, Stein-O\u2019Brien G, Augustin JJ, Slosberg J, Carosso GA, Winer B, et al. Universal prediction of cell-cycle position using transfer learning. Genome Biol. 2022;23(1):41.","journal-title":"Genome Biol"},{"issue":"10","key":"3768_CR59","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.cell.2022.03.033","volume":"185","author":"P Baldominos","year":"2022","unstructured":"Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho JW, et al. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell. 2022;185(10):1694-1708 e1619.","journal-title":"Cell"},{"key":"3768_CR60","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1038\/srep04012","volume":"4","author":"T Oki","year":"2014","unstructured":"Oki T, Nishimura K, Kitaura J, Togami K, Maehara A, Izawa K, et al. A novel cell-cycle-indicator, mVenus-p27K-, identifies quiescent cells and visualizes G0\u2013G1 transition. Sci Rep. 2014;4:4012.","journal-title":"Sci Rep"},{"issue":"7864","key":"3768_CR61","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-021-03614-z","volume":"594","author":"AL Correia","year":"2021","unstructured":"Correia AL, Guimaraes JC, Auf der Maur P, De Silva D, Trefny MP, Okamoto R, et al. Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature. 2021;594(7864):566\u201371.","journal-title":"Nature"},{"issue":"3","key":"3768_CR62","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1172\/JCI96329","volume":"128","author":"Y Liu","year":"2018","unstructured":"Liu Y, Lv J, Liu J, Liang X, Jin X, Xie J, et al. STAT3\/p53 pathway activation disrupts IFN-beta-induced dormancy in tumor-repopulating cells. J Clin Invest. 2018;128(3):1057\u201373.","journal-title":"J Clin Invest"},{"issue":"6","key":"3768_CR63","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00384-021-03888-9","volume":"36","author":"N Akdeniz","year":"2021","unstructured":"Akdeniz N, Kaplan MA, Uncu D, Inanc M, Kaya S, Dane F, et al. The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study. Int J Colorectal Dis. 2021;36(6):1311\u20139.","journal-title":"Int J Colorectal Dis"},{"issue":"36","key":"3768_CR64","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/onc.2017.135","volume":"36","author":"K Maurus","year":"2017","unstructured":"Maurus K, Hufnagel A, Geiger F, Graf S, Berking C, Heinemann A, et al. The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation. Oncogene. 2017;36(36):5110\u201321.","journal-title":"Oncogene"},{"issue":"1","key":"3768_CR65","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s13046-021-02150-y","volume":"40","author":"C Lanzi","year":"2021","unstructured":"Lanzi C, Favini E, Dal Bo L, Tortoreto M, Arrighetti N, Zaffaroni N, et al. Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma. J Exp Clin Cancer Res. 2021;40(1):381.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3768_CR66","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12967-025-07575-z","volume":"24","author":"CC Lee","year":"2025","unstructured":"Lee CC, Su YJ, Panda SS, Chiu CY, Wu CH, Lu TM, et al. <article-title update=\"added\">EpCAM activates the ERK-EGR1 signaling axis and promotes TNF-\u03b1-induced the progression of anaplastic thyroid cancer. J Transl Med. 2025;24(1):214.","journal-title":"J Transl Med"},{"issue":"1","key":"3768_CR67","doi-asserted-by":"publisher","first-page":"33996","DOI":"10.1038\/s41598-025-12967-8","volume":"15","author":"MT Ruckert","year":"2025","unstructured":"Ruckert MT, Walsh RM, Bye BA, Eades AE, Yan W, Bednar F, et al. DUSP6 is upregulated in metastasis and influences migration and metabolism in pancreatic cancer cells. Sci Rep. 2025;15(1):33996.","journal-title":"Sci Rep"},{"key":"3768_CR68","doi-asserted-by":"publisher","first-page":"121685","DOI":"10.1016\/j.jep.2026.121685","volume":"368","author":"N Wang","year":"2026","unstructured":"Wang N, Yang S, Li C, Wang Z, Ma Y, Lu W, et al. Huanglian Jiedu decoction ameliorates hypertensive nephropathy by inhibiting the AGEs-RAGE\/MAPK\/AP-1 axis: an integrated transcriptomics and network pharmacology study. J Ethnopharmacol. 2026;368:121685.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"3768_CR69","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","volume":"8","author":"ZD Shi","year":"2023","unstructured":"Shi ZD, Pang K, Wu ZX, Dong Y, Hao L, Qin JX, et al. Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduct Target Ther. 2023;8(1):113.","journal-title":"Signal Transduct Target Ther"},{"issue":"49","key":"3768_CR70","doi-asserted-by":"publisher","first-page":"e1904156","DOI":"10.1002\/adma.201904156","volume":"31","author":"P Zhang","year":"2019","unstructured":"Zhang P, Zhai Y, Cai Y, Zhao Y, Li Y. Nanomedicine-based immunotherapy for the treatment of cancer metastasis. Adv Mater. 2019;31(49):e1904156.","journal-title":"Adv Mater"},{"issue":"10","key":"3768_CR71","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s43018-022-00444-4","volume":"3","author":"F Shao","year":"2022","unstructured":"Shao F, Gao Y, Wang W, He H, Xiao L, Geng X, et al. Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade. Nat Cancer. 2022;3(10):1192\u2013210.","journal-title":"Nat Cancer"},{"issue":"14","key":"3768_CR72","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","volume":"76","author":"X Yang","year":"2016","unstructured":"Yang X, Lin Y, Shi Y, Li B, Liu W, Yin W, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res. 2016;76(14):4124\u201335.","journal-title":"Cancer Res"},{"issue":"1","key":"3768_CR73","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s43556-025-00371-7","volume":"6","author":"T Li","year":"2025","unstructured":"Li T, Liu R, Cao H, Deng S, Wang G, Wang X, et al. Epithelial membrane protein 1 drives hepatic stellate cell activation via the TLN1\/FAK cascade in MASLD donor liver transplantation. Mol Biomed. 2025;6(1):116.","journal-title":"Mol Biomed"},{"issue":"2","key":"3768_CR74","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.imlet.2011.03.010","volume":"138","author":"S Veenbergen","year":"2011","unstructured":"Veenbergen S, van Spriel AB. Tetraspanins in the immune response against cancer. Immunol Lett. 2011;138(2):129\u201336.","journal-title":"Immunol Lett"},{"issue":"10","key":"3768_CR75","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","volume":"24","author":"M Russo","year":"2024","unstructured":"Russo M, Chen M, Mariella E, Peng H, Rehman SK, Sancho E, et al. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. Nat Rev Cancer. 2024;24(10):694\u2013717.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"3768_CR76","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrc2256","volume":"7","author":"JA Aguirre-Ghiso","year":"2007","unstructured":"Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7(11):834\u201346.","journal-title":"Nat Rev Cancer"},{"key":"3768_CR77","doi-asserted-by":"crossref","unstructured":"Lee I, Kim E, Choi S, Kim D, Hong W, Choi J, Choi H, Kim J, Sable GA, Markkandan K, et al. A Raf-like kinase is required for smoke-induced seed dormancy in Arabidopsis thaliana. Proc Natl Acad Sci U S A. 2021;118(14):e2020636118.","DOI":"10.1073\/pnas.2020636118"},{"issue":"11","key":"3768_CR78","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","volume":"42","author":"C Galassi","year":"2024","unstructured":"Galassi C, Chan TA, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell. 2024;42(11):1825\u201363.","journal-title":"Cancer Cell"},{"issue":"7","key":"3768_CR79","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s43018-020-0088-5","volume":"1","author":"E Risson","year":"2020","unstructured":"Risson E, Nobre AR, Maguer-Satta V, Aguirre-Ghiso JA. The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nat Cancer. 2020;1(7):672\u201380.","journal-title":"Nat Cancer"},{"issue":"1","key":"3768_CR80","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/imr.13272","volume":"321","author":"P Holicek","year":"2024","unstructured":"Holicek P, Guilbaud E, Klapp V, Truxova I, Spisek R, Galluzzi L, et al. Type I interferon and cancer. Immunol Rev. 2024;321(1):115\u201327.","journal-title":"Immunol Rev"},{"issue":"7976","key":"3768_CR81","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41586-023-06464-z","volume":"620","author":"J Li","year":"2023","unstructured":"Li J, Hubisz MJ, Earlie EM, Duran MA, Hong C, Varela AA, et al. Non-cell-autonomous cancer progression from chromosomal instability. Nature. 2023;620(7976):1080\u20138.","journal-title":"Nature"},{"issue":"7962","key":"3768_CR82","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-023-06061-0","volume":"617","author":"H Yuan","year":"2023","unstructured":"Yuan H, Wu X, Wu Q, Chatoff A, Megill E, Gao J, et al. Lysine catabolism reprograms tumour immunity through histone crotonylation. Nature. 2023;617(7962):818\u201326.","journal-title":"Nature"},{"issue":"21","key":"3768_CR83","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1016\/j.cell.2021.09.019","volume":"184","author":"KC Lam","year":"2021","unstructured":"Lam KC, Araya RE, Huang A, Chen Q, Di Modica M, Rodrigues RR, et al. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell. 2021;184(21):5338-5356 e5321.","journal-title":"Cell"},{"issue":"1","key":"3768_CR84","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","volume":"37","author":"KJ Kurppa","year":"2020","unstructured":"Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, et al. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell. 2020;37(1):104-122 e112.","journal-title":"Cancer Cell"},{"issue":"1","key":"3768_CR85","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","volume":"11","author":"MH Hofmann","year":"2021","unstructured":"Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR, et al. BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discov. 2021;11(1):142\u201357.","journal-title":"Cancer Discov"},{"issue":"6","key":"3768_CR86","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2022.07.076","volume":"163","author":"J Datta","year":"2022","unstructured":"Datta J, Dai X, Bianchi A, De Castro Silva I, Mehra S, Garrido VT, et al. Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer. Gastroenterology. 2022;163(6):1593\u2013612.","journal-title":"Gastroenterology"},{"issue":"5","key":"3768_CR87","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1158\/0008-5472.CAN-20-1895","volume":"81","author":"JM Konen","year":"2021","unstructured":"Konen JM, Rodriguez BL, Padhye A, Ochieng JK, Gibson L, Diao L, et al. Dual inhibition of MEK and AXL targets tumor cell heterogeneity and prevents resistant outgrowth mediated by the epithelial-to-mesenchymal transition in NSCLC. Cancer Res. 2021;81(5):1398\u2013412.","journal-title":"Cancer Res"},{"issue":"4","key":"3768_CR88","doi-asserted-by":"publisher","first-page":"115541","DOI":"10.1016\/j.celrep.2025.115541","volume":"44","author":"B Zhao","year":"2025","unstructured":"Zhao B, Fang R, Schurmann H, Hemmer EJ, Mayer GL, Trajkovic-Arsic M, et al. PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. Cell Rep. 2025;44(4):115541.","journal-title":"Cell Rep"},{"key":"3768_CR89","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3389\/fonc.2018.00072","volume":"8","author":"AS Yadav","year":"2018","unstructured":"Yadav AS, Pandey PR, Butti R, Radharani NNV, Roy S, Bhalara SR, et al. The biology and therapeutic implications of tumor dormancy and reactivation. Front Oncol. 2018;8:72.","journal-title":"Front Oncol"},{"issue":"17","key":"3768_CR90","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381(17):1632\u201343.","journal-title":"N Engl J Med"},{"issue":"18","key":"3768_CR91","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1158\/0008-5472.CAN-22-0198","volume":"82","author":"AV Sorokin","year":"2022","unstructured":"Sorokin AV, Kanikarla Marie P, Bitner L, Syed M, Woods M, Manyam G, et al. Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4\/6. Cancer Res. 2022;82(18):3335\u201344.","journal-title":"Cancer Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03768-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03768-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03768-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:03:22Z","timestamp":1789430602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03768-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3768"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03768-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"10 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee for Animal Experimentation of Shanghai Yishang Biotechnology Co., Ltd. (Protocol Approval ID: IACUC-2025-NI-054). All procedures involving animals were conducted in accordance with the committee\u2019s guidelines and relevant national regulations for the care and use of laboratory animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"194"}}